MLYS Q3 2024 Earnings — Mineralys Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

MLYSMineralys Therapeutics, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$60M

Net Income

-$56M

EPS (Diluted)

$-1.13

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$50M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$268M

Total Liabilities

$31M

Stockholders' Equity

$237M

Cash & Equivalents

$97M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$60M	-$26M	-128.8%
Net Income	-$56M	-$23M	-147.5%